Anti-PD-L1 Monoclonal Antibody

BIOLOGICAL3 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, Yuanquan Yang, City of Hope Medical Center

Conditions

Advanced Malignant Solid NeoplasmColon NeoplasmHematopoietic and Lymphatic System NeoplasmLung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Phase 2

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

RecruitingNCT05914389

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityColon Neoplasm

Start: 2023-08-31End: 2030-08-31Target: 100Updated: 2023-08-08

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

RecruitingNCT06470971

Yuanquan YangAdvanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm

Start: 2024-07-09End: 2030-12-31Target: 40Updated: 2026-01-20

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

RecruitingNCT07288034

City of Hope Medical CenterLung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

Start: 2026-04-08End: 2028-10-08Target: 535Updated: 2026-04-15

Related Papers

Siltuximab for the prevention of severe immune-related adverse events during immune checkpoint inhibitor rechallenge in advanced cancer: First interim analysis of the CIRES trial.

Journal of Clinical Oncology2026-05-28